GPR89A

Across TCGA pan-cancer cohorts, GPR89A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GPR89A data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GPR89A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPR89A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD and UCEC are the cancer types where GPR89A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.086	0.659	<.001	21	view →
UCEC	DFS	Median	All	1.000	0.626	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GPR89A–STAD (DFS)

Open the STAD breakdown →